Medline $MDLN Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its holdings in Medline (NASDAQ:MDLN – Free Report) by 21.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 215,114 shares of the company’s stock after purchasing an additional 37,928 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Medline were worth $7,464,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDLN. Andra AP fonden acquired a new position in shares of Medline in the 2nd quarter valued at about $3,180,000. Baird Financial Group Inc. boosted its stake in shares of Medline by 1,151.5% in the second quarter. Baird Financial Group Inc. now owns 379,944 shares of the company’s stock worth $14,985,000 after buying an additional 349,584 shares during the last quarter. Cetera Investment Advisers boosted its stake in shares of Medline by 128.4% in the first quarter. Cetera Investment Advisers now owns 52,088 shares of the company’s stock worth $2,318,000 after buying an additional 29,282 shares during the last quarter. WINTON GROUP Ltd boosted its stake in shares of Medline by 1,263.0% in the second quarter. WINTON GROUP Ltd now owns 367,057 shares of the company’s stock worth $14,477,000 after buying an additional 340,127 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Medline during the second quarter worth about $2,466,000.

Analysts Set New Price Targets

A number of research analysts have issued reports on MDLN shares. Robert W. Baird set a $42.00 price target on Medline in a report on Thursday, August 6th. Weiss Ratings raised shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, November 9th. William Blair reaffirmed an “outperform” rating on shares of Medline in a research note on Wednesday, September 23rd. Citigroup lifted their target price on shares of Medline from $45.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Finally, Zacks Research cut shares of Medline from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Twenty-three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.08.

View Our Latest Stock Report on Medline

Insider Activity

In other news, major shareholder Private Ltd Gic sold 2,088,987 shares of Medline stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the sale, the insider owned 16,453,806 shares in the company, valued at $576,705,900.30. This trade represents a 11.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 6,348,676 shares of company stock valued at $224,525,137 in the last quarter. 0.81% of the stock is owned by company insiders.

Medline Price Performance

Medline stock opened at $39.47 on Monday. The stock has a market capitalization of $51.92 billion and a P/E ratio of 89.71. The company’s fifty day moving average price is $35.28 and its 200 day moving average price is $39.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.04. Medline has a 1 year low of $31.37 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. As a group, equities research analysts anticipate that Medline will post 1.58 earnings per share for the current fiscal year.

About Medline

(Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Read More

Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).

Institutional Ownership by Quarter for Medline (NASDAQ:MDLN)

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.